Skip to main content
Clinical Trials/IRCT20201227049851N1
IRCT20201227049851N1
Recruiting
Phase 3

Efficacy of Memantine augmentation in moderate to severe obsessive-compulsive symptoms

Kashan University of Medical Sciences0 sites30 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Obsessive-compulsive disorder.
Sponsor
Kashan University of Medical Sciences
Enrollment
30
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • All patients who suffer from obsessive\-compulsive disorder according to DSM V and clinical interview.
  • Patients who have Yale\-Brown Scores of 15 and above.
  • Patients who give written consent for participating in the study.

Exclusion Criteria

  • Patients who are diagnosed with a comorbid DSM V psychiatric diagnosis.
  • Patients who suffer from any systemic disease such as diabetes, hypo and hyperthyroidism,hypertension,hepatic failure or renal failure.
  • Patients who use alcohol or any other substance.
  • Patients who have received a psychotropic medicine during the last 6 months.
  • Women who are pregnant or breastfeeding or do not use any certain contraceptive method.
  • Patients who use concomitant somatic treatments.
  • Patients who are under treatment with Acetyl Cysteine, buprenorphine or any other medicine
  • Patients who receive any kind of psychotherapies.

Outcomes

Primary Outcomes

Not specified

Similar Trials